Restricted accessResearch articleFirst published online 1995-2
Significato e utilità clinica dell'Antigene Prostatico Specifico nella stadiazione del carcinoma prostatico. Valutazione su 70 prostatectomie radicali retropubiche * : Utility and clinical value of Prostate Specific Antigen in the staging of prostatic carcinoma. A study on 70 radical prostatectomies
Prostate specific antigen is the most important tumour marker in the study of prostatic cancer. The role of PSA in the management of prostatic carcinoma has been clarified in the diagnostic and prognostic stage, but several controversies persist over prediction of final pathological stage. We present our experience and discuss our results in 70 radical prostatectomies.
WangM.C., ValenzuelaL.A., MurphyG.P., ChuT.M.: Purification of a human prostate specific antigen. Invest. Urol., 17: 159–163, 1979.
2.
SassinA.M., ShulmanC..: Clinical use of prostate specific antigen in staging of patients with prostatic carcinoma. Eur. Urol.: 23, 348–351, 1993.
3.
BrawerM.K., BeatleJ., WenerM.H., VessellaR.L., PrestonS.D., LangeP.H.: Screening for prostatic carcinoma with prostate specific antigen: results of the second year. J. Urol., 150: 106–109, 1993.
4.
ColbergJ.W., SmithS.D., CatalonaW.J.: Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2,9 to 4.0 ng/ml. J. Urol., 149: 507–509, 1993.
5.
StameyT.A.: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. Monogr. Urol., 10: 49, 1989.
